Cel-Sci Corporation

CVM Healthcare Biotechnology

EPS
+65.4%
Free cash flow
−2.33%
Total debt
−39.7%

Quarter to June 2026, against a year earlier

1.45 0.08 +5.84%
Market cap
$24.1M
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
−1.63
Beneish M
−2.35
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(252.53%) (305.27%) (212.12%) (176.32%)

+8 more TTM periods

ROA
(108.91%) (114.90%) (97.99%) (92.16%)
ROIC
(169.59%) (147.48%) (146.58%) (145.08%)
Return on Tangible Assets
(324.19%) (719.09%) (314.90%) (202.56%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(1.38) (2.05) (2.12) (4.23)
Free Cash Flow
(16.75) (16.65) (17.00) (17.16)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026